2026-01-04 - Analysis Report
Okay, here's a comprehensive analysis of Natera Inc. (NTRA) based on the data provided.

**1. Return Rate vs. S&P 500 (VOO) & Alpha/Beta Analysis**

*   **NTRA:** Natera Inc. is a diagnostics company focused on cell-free DNA testing.
*   **Cumulative Return (NTRA):** 126.28%
*   **Cumulative Return (VOO):** 91.00%
*   **Divergence (NTRA vs VOO):** 35.3 (Relative Divergence: 47.5)

    *   NTRA has outperformed the S&P 500 over the tracked period, with a 35.3% higher cumulative return. The relative divergence of 47.5 indicates that the current divergence is near the middle of its historical range.

*   **Alpha/Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha    | Beta   | Cap(B) |
|------------|---------|--------|----------|--------|--------|
| 2016-2018  | 16.0%   | 56.0%  | 13.0%    | 1.5    | 1.9    |
| 2017-2019  | 49.0%   | 58.5%  | 32.0%    | 1.7    | 4.7    |
| 2018-2020  | 177.0%  | 58.5%  | 156.0%   | 1.3    | 13.9   |
| 2019-2021  | 89.0%   | 33.9%  | 46.0%    | 1.4    | 13.0   |
| 2020-2022  | -74.0%  | 76.8%  | -72.0%   | 1.4    | 5.6    |
| 2021-2023  | -183.0% | 76.8%  | -184.0%  | 1.6    | 8.7    |
| 2022-2024  | 11.0%   | 60.6%  | -9.0%    | 1.5    | 22.1   |
| 2023-2025  | 158.0%  | 39.0%  | 95.0%    | 1.3    | 31.9   |

    *   **CAGR:** Wide variation in annual growth, indicating high volatility.
    *   **MDD:** High Maximum Drawdown values suggest significant risk and price swings.
    *   **Alpha:** NTRA's alpha is positive in some periods (indicating outperformance relative to its beta), but negative in others (indicating underperformance). The alpha is very sensitive to the selected timeframe.
    *   **Beta:** NTRA generally has a beta above 1, suggesting it's more volatile than the market. The beta is fairly stable, ranging from 1.3 to 1.7
    *   **Cap:** NTRA Market capitalization generally increased over time.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** $228.84
*   **Previous Close:** $229.09
*   **Change:** -$0.11
*   **5-day SMA:** 230.59
*   **20-day SMA:** 232.74
*   **60-day SMA:** 212.51

    *   The stock price has experienced a minor decrease.
    *   The 5-day and 20-day SMAs are above the current price, suggesting potential short-term downward pressure. The 60-day SMA is significantly lower than the current price, suggesting a longer-term uptrend remains intact.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 45.74
*   **PPO:** -0.73
*   **Hybrid Signal:** Buy 100% of cash (4 shares - Very Safe - MRI:0.90), Monthly invest 0.8% of total investment ($1,000.00)
*   **Recent (20 days) Relative Divergence Change:** -2.0 (Short-term decrease)
*   **Expected Return (%):** -45.1%

    *   The MRI suggests a medium level of investment risk.
    *   The RSI is near the neutral level (50), indicating neither overbought nor oversold conditions.
    *   The negative PPO suggests the stock price is underperforming its moving average.
    *   The Hybrid Signal is recommending a "Buy" strategy.
    *   The negative expected return (-45.1%) is concerning, suggesting potential underperformance compared to the S&P 500 in the long term.
    *   The recent decrease in relative divergence indicates short-term downward momentum.

**4. Recent News & Significant Events**

*   **Positive Coverage:** Several articles highlight positive analyst opinions, price target increases (Barclays), and upgrades (Zacks).
*   **Valuation Concerns:** One article ("Assessing Valuation After a Multi-Year Share Price Surge") suggests the need to evaluate Natera's valuation after significant gains.
*   **Data and Acquisition News:** Articles discuss Foresight Acquisition and Signatera data, suggesting potential growth drivers or strategic moves.
*   **Technical Breakout:** Investor's Business Daily notes the stock is "hovering near buy point after 46% gain," indicating potential technical strength.
*   **Responsive Playbooks:** Stock Traders Daily references "NTRA Inflection," suggesting some potential turning point in the stock's trajectory.

    *   **Overall:** Recent news is mixed, with positive analyst sentiment balanced by valuation concerns. The news regarding data and potential acquisitions could be positive catalysts.

**4-2. Analyst Opinions**

*   **Consensus:** Strong Buy
*   **Mean Rating:** 1.47 (Near Strong Buy)
*   **Number of Opinions:** 19
*   **Target Price:**
    *   Average: $248.37
    *   High: $285.00
    *   Low: $186.00
*   **Recent Rating Changes:** Not provided, need more data on the values to make the comparision.

    *   Analysts are generally bullish on NTRA, with a consensus rating of "Strong Buy" and an average price target above the current price, suggesting potential upside.

**5. Recent Earnings Analysis**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2025-11-07 | -0.64  | 0.59 B$      |
| 2025-08-08 | -0.74  | 0.55 B$      |
| 2025-05-09 | -0.50  | 0.50 B$      |
| 2024-11-12 | -0.26  | 0.44 B$      |
| 2025-11-07 | -0.26  | 0.44 B$      |

    *   NTRA has consistently reported negative EPS (losses) over the past few quarters.
    *   Revenue has generally increased, but the company is not yet profitable.

**6. Financial Information (Revenue, Profitability, Capital)**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $0.59B     | 64.91%        |
| 2025-06-30   | $0.55B     | 63.41%        |
| 2025-03-31   | $0.50B     | 63.12%        |
| 2024-12-31   | $0.48B     | 62.94%        |
| 2024-09-30   | $0.44B     | 61.79%        |

*   Revenue is growing steadily.
*   Profit margins are high and also increasing, indicating efficient operations.

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30   | $1.25B     | -6.99%    |
| 2025-06-30   | $1.25B     | -8.10%    |
| 2025-03-31   | $1.24B     | -5.40%    |
| 2024-12-31   | $1.20B     | -4.50%    |
| 2024-09-30   | $0.88B     | -3.60%    |

*   Equity is generally increasing.
*   ROE is negative, reflecting the company's ongoing losses. However, ROE is improving slightly, suggesting a path towards profitability.

**7. Comprehensive Analysis (Summary)**

Natera Inc. is a volatile, high-growth diagnostics company. It has significantly outperformed the S&P 500 historically, but its stock price has significant fluctuations, and recent technical indicators suggest potential short-term downside. Analyst sentiment is generally positive, but there are some valuation concerns. The company is growing revenue at an impressive rate and operates with high profit margins but is still not profitable, with negative EPS and ROE. Recent news suggests potential growth drivers and strategic moves. The provided Hybrid Signal recommends a Buy. However, the negative Expected Return (%) implies possible long-term underperformance compared to the S&P 500.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.